In CRC-026T PDXs (KRAS G12D; high-affinity ligand, 84.2%; low-affinity ligand, 15.8%), TGII values for GC1118 and cetuximab were 47.9% (p = 0.006) and 97.5% (p = 0.053), respectively (p = 0.001; Figure 3A, lower panel and Table S2). The gene discussed is KRAS; the disease is colorectal carcinoma.